阿格列汀联合胰岛素泵持续皮下输注治疗门冬胰岛素30控制不佳的2型糖尿病患者的效果  

Efficacy of Alogliptin Combined with Continuous Subcutaneous Infusion of Insulin Pump in the Treatment of Patients with Type 2 Diabetes with Poorly Controlled Insulin Aspart 30

作　　者：黄建丽 马艳 HUANG Jianli;MA Yan(Department of Endocrinology and Nephrology,Lushi People’s Hospital,Sanmenxia 472000,China)

机构地区：[1]卢氏县人民医院内分泌肾病科,河南三门峡472000

出　　处：《河南医学研究》2021年第28期5319-5322,共4页Henan Medical Research

摘　　要：目的研究阿格列汀联合胰岛素治疗门冬胰岛素30控制不佳的2型糖尿病(T2DM)患者的效果。方法选取2020年1月至2021年1月于卢氏县人民医院就诊的门冬胰岛素30控制不佳的T2DM患者80例作为研究对象,依照治疗方案分为观察组和对照组,各40例。两组均接受常规干预,对照组接受常规胰岛素皮下输注治疗,观察组接受苯甲酸阿格列汀片联合胰岛素治疗。比较两组治疗效果,统计两组治疗前后血糖[糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后2 h血糖(2 h PG)]水平、血糖达标时间、胰岛素每日用量(血糖达标时)、不良反应发生率。结果两组治疗后总有效率比较,观察组[92.50%(37/40)]较对照组[67.50%(27/40)]高(P<0.05);治疗3个月后,观察组HbA1c、FPG、餐后2 h PG水平低于对照组(P<0.05);观察组血糖达标时间低于对照组,达标时每日胰岛素使用量低于对照组(P<0.05);对照组不良反应发生率与观察组比较,差异无统计学意义(P>0.05)。结论阿格列汀联合胰岛素泵持续皮下输注治疗门冬胰岛素30控制不佳的T2DM患者效果显著,能促进血糖达标,在减少胰岛素用量方面具有明显优势。Objective To study the effect of alogliptin and insulin in the treatment of patients with type 2 diabetes(T2DM)with poorly controlled insulin aspart 30.Methods Eighty patients with T2DM with poorly controlled insulin aspart 30 who were treated in Lushi People’s Hospital from January 2020 to January 2021 were selected as the research objects.According to the treatment plan,they were divided into observation group(40 cases)and control group(40 cases).The two groups were given conventional intervention.Control group was treated with conventional insulin subcutaneous infusion,and observation group was treated with alogliptin benzoate tablets combined with insulin.The therapeutic effects of the two groups were compared,and the levels of blood glucose[glycated hemoglobin(HbA1c),fasting blood glucose(FPG),2 hours postprandial blood glucose(2 h PG)],the time to reach the standard of blood glucose,the daily dose of insulin(when the standard of blood glucose was met)and the incidence of adverse reactions were recorded before and after treatment between the two groups.Results The total effective rate after treatment was compared between the two groups,and observation group rate was 92.50%(37/40),which was higher than that[67.50%(27/40)]of control group(P<0.05).After 3 months of treatment,the HbA1c,FPG,and 2 h PG levels of observation group were lower than those of control group(P<0.05).The time to reach the standard of blood glucose of observation group was lower than that of control group,and the daily dosage of insulin was lower than that of control group(P<0.05).There was no statistical difference in the incidence of adverse reactions between control group and observation group(P>0.05).Conclusion Alogliptin combined with insulin pump continuous subcutaneous infusion has a significant effect in the treatment of patients with T2DM with poorly controlled insulin aspart 30,which can promote blood glucose to reach the standard and has obvious advantages in reducing insulin dosage.

关 键 词：2型糖尿病 阿格列汀 胰岛素泵 门冬胰岛素30 血糖 

分 类 号：R587.1[医药卫生—内分泌]